CoChat

Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs)

Dwivedi, Avaneesh K., Gurjar, Vaishali, Kumar, Sanjit, Singh, Nagendra · 2015 · Drug Discovery Today
Cited by 61

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2015.03.004

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 98

  1. Vane, 1976, The mode of action of aspirin and similar compounds, J. Allergy Clin. Immunol., 58, 691, 10.1016/0091-6749(76)90181-0 · DOI · Paper page
  2. Vane, 2000, The fight against rheumatism: from willow bark to COX-1 sparing drugs, J. Physiol. Pharmacol., 51, 573
  3. Green, 2001, Understanding NSAIDs: from aspirin to COX-2, Clin. Cornerstone, 3, 50, 10.1016/S1098-3597(01)90069-9 · DOI · Paper page
  4. Allaj, 2013, Non-steroid anti-inflammatory drugs, prostaglandins, and cancer, Cell Biosci., 3, 8, 10.1186/2045-3701-3-8 · DOI
  5. Wallace, 2008, Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself?, Physiol. Rev., 88, 1547, 10.1152/physrev.00004.2008 · DOI · Paper page
  6. Wallace, 2013, Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy, World J. Gastroenterol., 19, 1861, 10.3748/wjg.v19.i12.1861 · DOI · Paper page
  7. Lanas, 1992, Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding, Gastroenterology, 103, 862, 10.1016/0016-5085(92)90018-T · DOI · Paper page
  8. McCarthy, 2009, GI bleeding: problems that persist, Gastrointest. Endosc., 70, 225, 10.1016/j.gie.2008.12.247 · DOI
  9. Stack, 2002, Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding, Aliment. Pharmacol. Ther., 16, 497, 10.1046/j.1365-2036.2002.01197.x · DOI · Paper page
  10. Hawkey, 1996, Non-steroidal anti-inflammatory drug gastropathy: causes and treatment, Scand. J. Gastroenterol. Suppl., 220, 124, 10.3109/00365529609094763 · doi:10.3109/00365529609094763
  11. Makris, 2010, Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review, J. Rheumatol., 37, 1236, 10.3899/jrheum.090935 · DOI
  12. McGettigan, 2013, Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries, PLoS Med., 10, e1001388, 10.1371/journal.pmed.1001388 · DOI · Paper page
  13. Scarpignato, 2013, Piroxicam-β-cyclodextrin: a GI safer piroxicam, Curr. Med. Chem., 20, 2415, 10.2174/09298673113209990115 · DOI
  14. Shau, 2012, Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence, BMC Cardiovasc. Disord., 12, 4, 10.1186/1471-2261-12-4 · DOI
  15. Sinha, 2013, Current perspectives in NSAID-induced gastropathy, Mediat. Inflamm., 2013, 258209, 10.1155/2013/258209 · DOI
  16. Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr. D: Biol. Crystallogr., 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
  17. DeLano, 2005, The case for open-source software in drug discovery, Drug Discov. Today, 10, 213, 10.1016/S1359-6446(04)03363-X · DOI
  18. Collaborative Computational Project, Number 4, 1994, The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D: Biol. Crystallogr., 50, 760, 10.1107/S0907444994003112 · DOI · Paper page
  19. Chandrasekharan, 2002, COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression, Proc. Natl. Acad. Sci. U. S. A., 99, 13926, 10.1073/pnas.162468699 · DOI · Paper page
  20. Gudis, 2005, The role of cyclooxygenase in gastric mucosal protection, Dig. Dis. Sci., 50, 16, 10.1007/s10620-005-2802-7 · DOI
  21. Simopoulos, 2002, Omega-3 fatty acids in inflammation and autoimmune diseases, J. Am. Coll. Nutr., 21, 495, 10.1080/07315724.2002.10719248 · DOI · Paper page
  22. Boursinos, 2009, Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing?, J. Musculoskelet. Neuronal Interact., 9, 44
  23. Hennan, 2001, Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries, Circulation, 104, 820, 10.1161/hc3301.092790 · DOI · Paper page
  24. Mattia, 2005, COX-2 inhibitors: pharmacological data and adverse effects, Minerva Anestesiol., 71, 461
  25. McGeer, 2001, Cardiovascular events and COX-2 inhibitors, JAMA, 286, 2810
  26. Patrignani, 2008, Risk management profile of etoricoxib: an example of personalized medicine, Ther. Clin. Risk Manag., 4, 983, 10.2147/TCRM.S3209 · DOI
  27. Picot, 1994, The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1, Nature, 367, 243, 10.1038/367243a0 · DOI · Paper page
  28. Rimon, 2010, Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1, Proc. Natl. Acad. Sci. U. S. A., 107, 28, 10.1073/pnas.0909765106 · DOI · Paper page
  29. Loll, 2001, O-acetylsalicylhydroxamic acid, a novel acetylating inhibitor of prostaglandin H2 synthase: structural and functional characterization of enzyme–inhibitor interactions, Mol. Pharmacol., 60, 1407, 10.1124/mol.60.6.1407 · doi:10.1124/mol.60.6.1407
  30. Selinsky, 2001, Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations, Biochemistry, 40, 5172, 10.1021/bi010045s · DOI · Paper page
  31. Sidhu, 2010, Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers, Biochemistry, 49, 7069, 10.1021/bi1003298 · DOI · Paper page
  32. Kurumbail, 1996, Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature, 384, 644, 10.1038/384644a0 · DOI · Paper page
  33. Duggan, 2010, Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen, J. Biol. Chem., 285, 34950, 10.1074/jbc.M110.162982 · DOI · Paper page
  34. Rowlinson, 2003, A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385, J. Biol. Chem., 278, 45763, 10.1074/jbc.M305481200 · DOI · Paper page
  35. Wang, 2010, The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life, Bioorg. Med. Chem. Lett., 20, 7159, 10.1016/j.bmcl.2010.07.054 · DOI · Paper page
  36. Tacconelli, 2002, The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity, Curr. Med. Res. Opin., 18, 503, 10.1185/030079902125001335 · DOI
  37. Singh, 2004, Phospholipase A2 as a target protein for nonsteroidal anti-inflammatory drugs (NSAIDS): crystal structure of the complex formed between phospholipase A2 and oxyphenbutazone at 1.6Å resolution, Biochemistry, 43, 14577, 10.1021/bi0483561 · doi:10.1021/bi0483561
  38. Singh, 2009, Simultaneous inhibition of anti-coagulation and inflammation: crystal structure of phospholipase A2 complexed with indomethacin at 1.4Å resolution reveals the presence of the new common ligand-binding site, J. Mol. Recognit., 22, 437, 10.1002/jmr.960 · doi:10.1002/jmr.960
  39. Singh, 2005, Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 angstroms resolution, J. Drug Target., 13, 113, 10.1080/10611860400024078 · doi:10.1080/10611860400024078
  40. Singh, 2006, Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7Å resolution, Acta Crystallogr. D: Biol. Crystallogr., 62, 410, 10.1107/S0907444906003660 · DOI
  41. Kaplan, 1978, Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes, Proc. Natl. Acad. Sci. U. S. A., 75, 2955, 10.1073/pnas.75.6.2955 · DOI
  42. Wu, 2008, Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2, Structure, 16, 1714, 10.1016/j.str.2008.09.007 · DOI
  43. Lovering, 2004, Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin, Cancer Res., 64, 1802, 10.1158/0008-5472.CAN-03-2847 · DOI · Paper page
  44. Watanabe, 1992, Relation between cytochrome P-450 increase and endoplasmic reticulum proliferation in hepatocytes of mice treated with phenobarbital: a microphotometric and morphometric study, J. Histochem. Cytochem., 40, 353, 10.1177/40.3.1552174 · doi:10.1177/40.3.1552174
  45. Guengerich, 2008, Cytochrome p450 and chemical toxicology, Chem. Res. Toxicol., 21, 70, 10.1021/tx700079z · DOI · Paper page
  46. Degtyarenko, 1995, Structural domains of P450-containing monooxygenase systems, Protein Eng., 8, 737, 10.1093/protein/8.8.737 · doi:10.1093/protein/8.8.737
  47. Wester, 2004, The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution, J. Biol. Chem., 279, 35630, 10.1074/jbc.M405427200 · DOI · Paper page
  48. Zhu, 2012, Role of intestinal cytochrome p450 enzymes in diclofenac-induced toxicity in the small intestine, J. Pharmacol. Exp. Ther., 343, 362, 10.1124/jpet.112.198077 · DOI
  49. Kishida, 2012, Increase in covalent binding of 5-hydroxydiclofenac to hepatic tissues in rats co-treated with lipopolysaccharide and diclofenac: involvement in the onset of diclofenac-induced idiosyncratic hepatotoxicity, J. Toxicol. Sci., 37, 1143, 10.2131/jts.37.1143 · DOI
  50. Van Zyl, 1979, The influence of non-steroidal anti-inflammatory and antithyroid agents on myeloperoxidase-catalysed activities of human leucocytes, South Afr. Med. J., 55, 1082
  51. Chatterjee, 1993, Inhibition of intestinal peroxidase activity by nonsteroidal antiinflammatory drugs, Biochim. Biophys. Acta, 1161, 168, 10.1016/0167-4838(93)90210-I · doi:10.1016/0167-4838(93)90210-i
  52. Singh, 2009, Binding modes of aromatic ligands to mammalian heme peroxidases with associated functional implications: crystal structures of lactoperoxidase complexes with acetylsalicylic acid, salicylhydroxamic acid, and benzylhydroxamic acid, J. Biol. Chem., 284, 20311, 10.1074/jbc.M109.010280 · DOI
  53. Foss, 2005, The pathway by which the tetrameric protein transthyretin dissociates, Biochemistry, 44, 15525, 10.1021/bi051608t · DOI · Paper page
  54. Andrade, 1952, A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves, Brain J. Neurol., 75, 408, 10.1093/brain/75.3.408 · DOI · Paper page
  55. Coelho, 1996, Familial amyloid polyneuropathy: new developments in genetics and treatment, Curr. Opin. Neurol., 9, 355, 10.1097/00019052-199610000-00007 · DOI · Paper page
  56. Jacobson, 1997, Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans, N. Engl. J. Med., 336, 466, 10.1056/NEJM199702133360703 · DOI · Paper page
  57. Westermark, 1990, Fibril in senile systemic amyloidosis is derived from normal transthyretin, Proc. Natl. Acad. Sci. U. S. A., 87, 2843, 10.1073/pnas.87.7.2843 · DOI · Paper page
  58. Klabunde, 2000, Rational design of potent human transthyretin amyloid disease inhibitors, Nat. Struct. Biol., 7, 312, 10.1038/74082 · DOI
  59. Mir, 2009, The structural basis for the prevention of nonsteroidal antiinflammatory drug-induced gastrointestinal tract damage by the C-lobe of bovine colostrum lactoferrin, Biophys. J., 97, 3178, 10.1016/j.bpj.2009.09.030 · DOI
  60. Troost, 2003, Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers, Eur. J. Clin. Nutr., 57, 1579, 10.1038/sj.ejcn.1601727 · DOI
  61. Yang, 2007, Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin, J. Struct. Biol., 157, 348, 10.1016/j.jsb.2006.08.015 · DOI · Paper page
  62. Evans, 2004, PPARs and the complex journey to obesity, Nat. Med., 10, 355, 10.1038/nm1025 · DOI · Paper page
  63. Lehrke, 2005, The many faces of PPARgamma, Cell, 123, 993, 10.1016/j.cell.2005.11.026 · DOI · Paper page
  64. McKenna, 2009, Minireview: evolution of NURSA, the nuclear receptor signaling atlas, Mol. Endocrinol., 23, 740, 10.1210/me.2009-0135 · DOI · Paper page
  65. Hamblin, 2009, PPARs and the cardiovascular system, Antioxid. Redox Signal., 11, 1415, 10.1089/ars.2008.2280 · DOI · Paper page
  66. Li, 2008, Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties, Diabetes Obes. Metab., 10, 10, 10.1111/j.1463-1326.2007.00708.x · DOI · Paper page
  67. Waki, 2007, The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression, Cell Metab., 5, 357, 10.1016/j.cmet.2007.03.010 · DOI · Paper page
  68. Walczak, 2002, PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism, J. Lipid Res., 43, 177, 10.1016/S0022-2275(20)30159-0 · DOI · Paper page
  69. Waku, 2010, The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites, EMBO J., 29, 3395, 10.1038/emboj.2010.197 · DOI · Paper page
  70. Owen, 2000, The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p, EMBO J., 19, 6141, 10.1093/emboj/19.22.6141 · DOI · Paper page
  71. Zeng, 2002, Bromodomain: an acetyl-lysine binding domain, FEBS Lett., 513, 124, 10.1016/S0014-5793(01)03309-9 · DOI · Paper page
  72. Beck, 1992, A homologue of the Drosophila female sterile homeotic (fsh) gene in the class II region of the human MHC, J. DNA Seq. Mapp., 2, 203, 10.3109/10425179209020804 · DOI · Paper page
  73. Chung, 2012, Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery, J. Med. Chem., 55, 576, 10.1021/jm201320w · DOI · Paper page
  74. Gosmini, 2014, The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor, J. Med. Chem., 57, 8111, 10.1021/jm5010539 · DOI · Paper page
  75. Ciolino, 2006, Sulindac regulates the aryl hydrocarbon receptor-mediated expression of phase 1 metabolic enzymes in vivo and in vitro, Carcinogenesis, 27, 1586, 10.1093/carcin/bgi359 · DOI
  76. Hu, 2007, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro, Mol. Pharmacol., 71, 1475, 10.1124/mol.106.032748 · DOI · Paper page
  77. Abdelrahim, 2006, Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation, J. Natl. Cancer Inst., 98, 855, 10.1093/jnci/djj232 · DOI · Paper page
  78. Abdelrahim, 2004, Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells, Cancer Res., 64, 6740, 10.1158/0008-5472.CAN-04-0713 · DOI · Paper page
  79. Abdelrahim, 2005, Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins, Mol. Pharmacol., 68, 317, 10.1124/mol.105.011825 · DOI
  80. Pathi, 2014, Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors, Mol. Carcinog., 53, E53
  81. Imbimbo, 2010, Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?, Front. Aging Neurosci., 2
  82. Perrone, 2015, Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: preliminary investigation, Pharmacology, 95, 22, 10.1159/000369826 · DOI
  83. Lu, 2015, FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach, Sci. Rep., 5, 8114, 10.1038/srep08114 · DOI
  84. Joo, 2014, Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC–MS/MS, Biopharm. Drug Dispos.
  85. Frolov, 2012, Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791, PLOS ONE, 7, e38759, 10.1371/journal.pone.0038759 · doi:10.1371/journal.pone.0038759
  86. Martelli, 2013, Pharmacol. Res., 78, 1, 10.1016/j.phrs.2013.09.008 · DOI
  87. Eren, 2010, Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors, Bioorg. Med. Chem., 18, 6367, 10.1016/j.bmc.2010.07.009 · DOI
  88. Tietz, 2013, Synthesis of three 18F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold, Org. Biomol. Chem., 11, 8052, 10.1039/c3ob41935e · DOI
  89. Consalvi, 2015, Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors, Bioorg. Med. Chem., 23, 810, 10.1016/j.bmc.2014.12.041 · doi:10.1016/j.bmc.2014.12.041
  90. Gupta, 2004, Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors, Bioorg. Med. Chem. Lett., 14, 667, 10.1016/j.bmcl.2003.11.034 · doi:10.1016/j.bmcl.2003.11.034
  91. Chan, 1999, Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther., 290, 551, 10.1016/S0022-3565(24)34934-1 · DOI · Paper page
  92. Viegas, 2011, Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR, J. Med. Chem., 54, 8555, 10.1021/jm201090k · doi:10.1021/jm201090k
  93. Riendeau, 2001, Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2, J. Pharmacol. Exp. Ther., 296, 558, 10.1016/S0022-3565(24)38776-2 · DOI · Paper page
  94. Warner, 1999, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl. Acad. Sci. U. S. A., 96, 7563, 10.1073/pnas.96.13.7563 · DOI · Paper page
  95. Wester, 2003, Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1Å resolution: evidence for an induced fit model of substrate binding, Biochemistry, 42, 9335, 10.1021/bi034556l · DOI · Paper page
  96. Milojevic, 2009, Human serum albumin inhibits Abeta fibrillization through a monomer-competitor mechanism, Biophys. J., 97, 2585, 10.1016/j.bpj.2009.08.028 · DOI
  97. Desfosses, 1991, Ligand binding at membrane mimetic interfaces. Human serum albumin in reverse micelles, Eur. J. Biochem. FEBS, 199, 79, 10.1111/j.1432-1033.1991.tb16094.x · doi:10.1111/j.1432-1033.1991.tb16094.x
  98. Honoré, 1983, Interaction of indomethacin with adult human albumin and neonatal serum, Dev. Pharmacol. Ther., 6, 347, 10.1159/000457335 · doi:10.1159/000457335

Cited by

Metadata

Authors
Dwivedi, A. K., Gurjar, V., Kumar, S., & Singh, N.
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2015-07
Volume
20
Issue
7
Pages
863-873
ISSN
1359-6446
Cited by
61
References
5
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • ICMR
  • DST

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.